Skip to main content

Table 1 Glycoprotein IIb/IIIa antagonists

From: Novel agents for anti-platelet therapy

Agents

Mechanism of action

Administration

Main side effects

State

Abciximab

inhibit GPIIb/IIIa receptor and GP αIIb/β3 receptor

IV

allergy, bleeding,

thrombocytopenia

Approved

Eptifibatide

inhibit GPIIb/IIIa receptor

IV

bleeding,

thrombocytopenia

Approved

Tirofiban

inhibit GP IIb/IIIa receptor

IV

bleeding,

thrombocytopenia

approved

  1. Abbreviations: GP: glycoprotein; IV: intravenous.